On the public citation graph
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
0 signed · 690 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamadermatol.2015.2707openalex-snapshot
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
inferredcites →https://doi.org/10.1007/s10637-013-9939-6openalex-snapshot
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
inferredcites →https://doi.org/10.1007/s10637-014-0092-7openalex-snapshot
Kidney injuries related to ipilimumab
inferredcites →https://doi.org/10.1007/s40618-015-0301-zopenalex-snapshot
Ipilimumab-induced hypophysitis: review of the literature
inferredcites →https://doi.org/10.1016/j.adengl.2016.01.016openalex-snapshot
Pembrolizumab: a New Drug That Can Induce Exacerbations of Psoriasis
inferredcites →https://doi.org/10.1016/s1074-7613(00)80089-8openalex-snapshot
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
inferredcites →https://doi.org/10.1016/s1470-2045(09)70334-1openalex-snapshot
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
inferredcites →https://doi.org/10.1016/s1470-2045(15)70076-8openalex-snapshot
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
inferredcites →https://doi.org/10.1055/s-0031-1291603openalex-snapshot
Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis
inferredcites →https://doi.org/10.1056/nejmc0904283openalex-snapshot
Anti-CTLA4 Antibody–Induced Lupus Nephritis
inferredcites →https://doi.org/10.1056/nejme1205943openalex-snapshot
Tumor Immunotherapy Directed at PD-1
inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1104621openalex-snapshot
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
inferredcites →https://doi.org/10.1056/nejmoa1305133openalex-snapshot
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1412082openalex-snapshot
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-snapshot
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot
Pembrolizumab versus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1093/annonc/mdq013openalex-snapshot
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
inferredcites →https://doi.org/10.1093/annonc/mdv139openalex-snapshot
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
inferredcites →https://doi.org/10.1093/annonc/mdv383openalex-snapshot
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
inferredcites →https://doi.org/10.1093/intimm/dxm057openalex-snapshot
PD-1 and PD-1 ligands: from discovery to clinical application
inferredcites →https://doi.org/10.1097/cji.0000000000000081openalex-snapshot
Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab
inferredcites →https://doi.org/10.1097/cmr.0000000000000155openalex-snapshot
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
inferredcites →https://doi.org/10.1097/cmr.0000000000000191openalex-snapshot
Acute skin reaction suggestive of pembrolizumab-induced radiosensitization
inferredcites →https://doi.org/10.1097/cmr.0b013e32835c7e68openalex-snapshot
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
inferredcites →https://doi.org/10.1111/jdv.13336openalex-snapshot
Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-2872openalex-snapshot
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
inferredcites →https://doi.org/10.1158/2326-6066.cir-13-0146openalex-snapshot
Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
inferredcites →https://doi.org/10.1200/jco.2011.41.4359openalex-snapshot
Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss
inferredcites →https://doi.org/10.1200/jco.2013.49.0565openalex-snapshot
Acute Radiation Skin Toxicity Associated With BRAF Inhibitors
inferredcites →https://doi.org/10.1200/jco.2013.53.0105openalex-snapshot
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
inferredcites →https://doi.org/10.1200/jco.2014.60.0379openalex-snapshot
Toxicities of Immunotherapy for the Practitioner
inferredcites →https://doi.org/10.1200/jco.2015.33.18_suppl.lba101openalex-snapshot
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
inferredcites →https://doi.org/10.1210/jc.2012-4075openalex-snapshot
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
inferredcites →https://doi.org/10.1371/journal.pone.0053745openalex-snapshot
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
inferredcites →https://doi.org/10.14694/edbook_am.2015.35.76openalex-snapshot
Managing Immune Checkpoint-Blocking Antibody Side Effects
inferredcites →https://doi.org/10.2337/dc15-1331openalex-snapshot
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
inferredcites →https://doi.org/10.2340/00015555-2212openalex-snapshot
Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4748520openalex-extracted
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1001/jamadermatol.2017.2106openalex-snapshot
Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamadermatol.2017.5670openalex-snapshot
Generalized Lichen Nitidus Following Anti–PD-1 Antibody Treatment
inferred← citeshttps://doi.org/10.1001/jamaoncol.2017.2391openalex-snapshot
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4485openalex-snapshot
Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.6431openalex-snapshot
Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.5570openalex-snapshot
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.4318openalex-snapshot
Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1002/9781119709268.rook144openalex-snapshot
Systemic Treatment of Melanoma
inferred← citeshttps://doi.org/10.1002/adma.202004559openalex-snapshot
Biopolymer Immune Implants’ Sequential Activation of Innate and Adaptive Immunity for Colorectal Cancer Postoperative Immunotherapy
inferred← citeshttps://doi.org/10.1002/cam4.1145openalex-snapshot
Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
inferred← citeshttps://doi.org/10.1002/cam4.5183openalex-snapshot
Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials
inferred← citeshttps://doi.org/10.1002/ccr3.4574openalex-snapshot
Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases
inferred← citeshttps://doi.org/10.1002/ccr3.71599openalex-snapshot
Aseptic Sinusitis: A New Phenotype of Immune‐Related Rhinosinusitis in the Era of Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1002/dmrr.3366openalex-snapshot
Diabetes mellitus induced by immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1002/ijc.34813openalex-snapshot
Analysis of immune‐related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1002/jppr.1436openalex-snapshot
Pembrolizumab: a case of drug‐induced autoimmune diabetes mellitus and colitis
inferred← citeshttps://doi.org/10.1002/osi2.1113openalex-snapshot
A case of lichenoid oral mucositis associated with nivolumab therapy
inferred← citeshttps://doi.org/10.1002/pdi.2129openalex-snapshot
Immune‐mediated diabetes due to pembrolizumab
inferred← citeshttps://doi.org/10.1002/rcr2.525openalex-snapshot
Pembrolizumab‐related pancreatitis with elevation of pancreatic tumour markers
inferred← citeshttps://doi.org/10.1002/ski2.287openalex-snapshot
Radiotherapy May Exacerbated Anti-Programmed Cell Death 1 Treatment Induced Vitiligo: A Case Report
inferred← citeshttps://doi.org/10.1002/ski2.8openalex-snapshot
Extensive Mucocutaneous, Oesophageal and Otic Lichen Planus Secondary to Nivolumab Therapy
inferred← citeshttps://doi.org/10.1007/16833_2022_64openalex-snapshot
Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers
inferred← citeshttps://doi.org/10.1007/978-1-4614-7147-9_22openalex-snapshot
Side Effects of Systemic Therapy and Their Clinical Management
inferred← citeshttps://doi.org/10.1007/978-1-4614-7322-0_22-1openalex-snapshot
Side Effects of Systemic Therapy and Their Clinical Management
inferred← citeshttps://doi.org/10.1007/978-3-030-02505-2_8openalex-snapshot
Immune Checkpoint Inhibitors-Induced Hepatitis
inferred← citeshttps://doi.org/10.1007/978-3-030-41008-7_14openalex-snapshot
Hepatobiliary Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-50593-6_17openalex-snapshot
Management of Skin Cancers in Solid Organ Transplant Recipients
inferred← citeshttps://doi.org/10.1007/978-3-030-74028-3_7openalex-snapshot
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_13openalex-snapshot
Hepatobiliary and Pancreatic Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_242-1openalex-snapshot
Immunotherapy and Endocrine Oncology
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_242-2openalex-snapshot
Immunotherapy for Endocrine Oncology
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-1openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-2openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-031-00241-0_7openalex-snapshot
Hepatology (Liver and Bile Duct)
inferred← citeshttps://doi.org/10.1007/978-3-031-20999-4_45openalex-snapshot
Post-transplant Malignancies
inferred← citeshttps://doi.org/10.1007/978-3-031-75480-7_6openalex-snapshot
Immunotherapy for Breast Cancer Survivors: Implications for Clinical Practice
inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_56openalex-snapshot
A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy
inferred← citeshttps://doi.org/10.1007/978-3-032-00769-8_242openalex-snapshot
Immunotherapy for Endocrine Oncology
inferred← citeshttps://doi.org/10.1007/978-3-319-62431-0_34openalex-snapshot
Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting
inferred← citeshttps://doi.org/10.1007/978-3-319-70253-7_12openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-319-74588-6_81openalex-snapshot
Adrenal Emergencies in Critically Ill Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_81-1openalex-snapshot
Adrenal Emergencies in Critically Ill Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_81-2openalex-snapshot
Adrenal Emergencies in Critically Ill Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-319-78310-9_36openalex-snapshot
Immune-Related Adverse Toxicities and Clinical Management
inferred← citeshttps://doi.org/10.1007/978-3-662-58012-7_5openalex-snapshot
Nebenwirkungen und Supportivtherapie
inferred← citeshttps://doi.org/10.1007/s00105-017-4117-yopenalex-snapshot
Lichenoide Arzneimittelreaktionen
inferred← citeshttps://doi.org/10.1007/s00105-024-05352-5openalex-snapshot
Alopezie durch Chemotherapeutika, Hedgehog-Inhibitoren, zielgerichtete Antikörpertherapien und Immuncheckpointinhibitoren
inferred← citeshttps://doi.org/10.1007/s00117-025-01549-4openalex-snapshot
Nebenwirkungen von Immuntherapien
inferred← citeshttps://doi.org/10.1007/s00259-022-06084-1openalex-snapshot
Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy
inferred← citeshttps://doi.org/10.1007/s00261-017-1050-6openalex-snapshot
Biliary and pancreatic complications of molecular targeted therapies in cancer imaging
inferred← citeshttps://doi.org/10.1007/s00261-020-02531-5openalex-snapshot
Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists
inferred← citeshttps://doi.org/10.1007/s00262-016-1913-7openalex-snapshot
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
inferred← citeshttps://doi.org/10.1007/s00262-017-2033-8openalex-snapshot
Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review
inferred← citeshttps://doi.org/10.1007/s00262-017-2107-7openalex-snapshot
Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report
inferred← citeshttps://doi.org/10.1007/s00262-018-2178-0openalex-snapshot
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
inferred← citeshttps://doi.org/10.1007/s00262-018-2203-3openalex-snapshot
Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC
inferred← citeshttps://doi.org/10.1007/s00262-020-02555-2openalex-snapshot
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
inferred← citeshttps://doi.org/10.1007/s00292-017-0281-1openalex-snapshot
Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren
inferred← citeshttps://doi.org/10.1007/s00292-018-0519-6openalex-snapshot
Leberschaden durch Therapie mit Immun-Checkpoint-Inhibitoren
inferred← citeshttps://doi.org/10.1007/s00403-020-02094-xopenalex-snapshot
Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00428-017-2267-zopenalex-snapshot
Immune checkpoint inhibitor colitis: the flip side of the wonder drugs
inferred← citeshttps://doi.org/10.1007/s00520-017-3629-4openalex-snapshot
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00520-020-05706-4openalex-snapshot
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00520-026-10945-yopenalex-snapshot
Diagnosis and management of immune checkpoint inhibitor–induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review
inferred← citeshttps://doi.org/10.1007/s00535-024-02083-1openalex-snapshot
Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy
inferred← citeshttps://doi.org/10.1007/s10637-025-01517-8openalex-snapshot
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis
inferred← citeshttps://doi.org/10.1007/s10753-021-01430-1openalex-snapshot
PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis
inferred← citeshttps://doi.org/10.1007/s11523-017-0495-4openalex-snapshot
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/s11523-022-00940-8openalex-snapshot
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s11523-024-01098-1openalex-snapshot
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s11864-018-0562-9openalex-snapshot
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
inferred← citeshttps://doi.org/10.1007/s11864-020-0721-7openalex-snapshot
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
inferred← citeshttps://doi.org/10.1007/s11886-020-01315-zopenalex-snapshot
PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity
inferred← citeshttps://doi.org/10.1007/s11934-017-0704-9openalex-snapshot
The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility
inferred← citeshttps://doi.org/10.1007/s12094-019-02161-4openalex-snapshot
Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
inferred← citeshttps://doi.org/10.1007/s12325-020-01386-yopenalex-snapshot
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
inferred← citeshttps://doi.org/10.1007/s12328-020-01317-yopenalex-snapshot
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
inferred← citeshttps://doi.org/10.1007/s12328-022-01731-4openalex-snapshot
Immune-related colitis and pancreatitis treated with infliximab
inferred← citeshttps://doi.org/10.1007/s12672-024-01119-5openalex-snapshot
Immunotherapy for small cell lung cancer: the current state and future trajectories
inferred← citeshttps://doi.org/10.1007/s13340-018-0362-2openalex-snapshot
Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy
inferred← citeshttps://doi.org/10.1007/s15011-021-4741-9openalex-snapshot
Fortschritte bei Systemtherapie verbessern Prognose
inferred← citeshttps://doi.org/10.1007/s15011-023-5981-7openalex-snapshot
Nebenwirkungen frühzeitig erkennen und erfolgreich managen
inferred← citeshttps://doi.org/10.1007/s15012-017-2304-2openalex-snapshot
Optimale Systemtherapie beim kutanen Melanom
inferred← citeshttps://doi.org/10.1007/s15012-017-2373-2openalex-snapshot
Melanom: breites Spektrum an Nebenwirkungen
inferred← citeshttps://doi.org/10.1007/s15015-017-2983-xopenalex-snapshot
Optimale Systemtherapie beim kutanen Melanom
inferred← citeshttps://doi.org/10.1007/s15015-017-3180-7openalex-snapshot
Melanom: Breites Spektrum an Nebenwirkungen unter Anti-PD-1-Antikörpern
inferred← citeshttps://doi.org/10.1007/s40257-017-0336-3openalex-snapshot
Dermatologic Reactions to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/s40264-018-0774-8openalex-snapshot
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
inferred← citeshttps://doi.org/10.1007/s40290-018-0231-0openalex-snapshot
Immunogenicity Assessment of Biosimilars
inferred← citeshttps://doi.org/10.1007/s40618-018-0984-zopenalex-snapshot
Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)
inferred← citeshttps://doi.org/10.1007/s40618-020-01480-6openalex-snapshot
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
inferred← citeshttps://doi.org/10.1007/s40674-019-00131-zopenalex-snapshot
Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments
inferred← citeshttps://doi.org/10.1007/s41971-019-00061-6openalex-snapshot
Medikamentös induzierte akute Pankreatitis
inferred← citeshttps://doi.org/10.1007/s42399-020-00670-wopenalex-snapshot
Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management
inferred← citeshttps://doi.org/10.1016/b978-0-443-15842-1.00028-4openalex-snapshot
Drug-induced immunotoxicity
inferred← citeshttps://doi.org/10.1016/b978-0-443-41638-5.00006-5openalex-snapshot
Immunotherapy and gastrointestinal-related side effects in patients with cancers
inferred← citeshttps://doi.org/10.1016/b978-0-7020-6275-9.00011-8openalex-snapshot
10.1016/b978-0-7020-6275-9.00011-8
inferred← citeshttps://doi.org/10.1016/b978-3-437-21011-2.00013-2openalex-snapshot
Niere und Elektrolyte, Osteoprotektion
inferred← citeshttps://doi.org/10.1016/b978-3-437-23824-6.00013-4openalex-snapshot
Niere und Elektrolyte, Osteoprotektion
inferred← citeshttps://doi.org/10.1016/bs.seda.2017.06.027openalex-snapshot
Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies
inferred← citeshttps://doi.org/10.1016/j.abd.2021.09.022openalex-snapshot
Umbilical lichen planus induced by nivolumab
inferred← citeshttps://doi.org/10.1016/j.abdp.2023.05.012openalex-snapshot
10.1016/j.abdp.2023.05.012
inferred← citeshttps://doi.org/10.1016/j.acra.2022.03.007openalex-snapshot
Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review
inferred← citeshttps://doi.org/10.1016/j.ad.2016.05.019openalex-snapshot
Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
inferred← citeshttps://doi.org/10.1016/j.addr.2017.05.011openalex-snapshot
Delivering safer immunotherapies for cancer
inferred← citeshttps://doi.org/10.1016/j.adengl.2016.05.029openalex-snapshot
Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
inferred← citeshttps://doi.org/10.1016/j.ajhg.2023.05.013openalex-snapshot
Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility
inferred← citeshttps://doi.org/10.1016/j.ajpath.2021.07.007openalex-snapshot
mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.amjms.2022.02.010openalex-snapshot
Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma
inferred← citeshttps://doi.org/10.1016/j.anai.2021.02.009openalex-snapshot
Immune-related cutaneous adverse events due to checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.ando.2018.07.006openalex-snapshot
Expert opinion on immunotherapy induced diabetes
inferred← citeshttps://doi.org/10.1016/j.annder.2018.01.047openalex-snapshot
Toxicités dermatologiques des inhibiteurs de checkpoint immunologiques
inferred← citeshttps://doi.org/10.1016/j.annder.2019.04.021openalex-snapshot
Lymphome cérébral primitif après immunothérapie d’un mélanome métastatique
inferred← citeshttps://doi.org/10.1016/j.annder.2019.07.008openalex-snapshot
Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review
inferred← citeshttps://doi.org/10.1016/j.annder.2022.11.012openalex-snapshot
Oral mucosal toxicities induced by immune checkpoint inhibitors: Clinical features and algorithm management
inferred← citeshttps://doi.org/10.1016/j.annpat.2018.07.005openalex-snapshot
Effets secondaires digestifs et hépatiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors : anti-CTLA-4 et anti-PD-1/PD-L1) : aspects anatomocliniques
inferred← citeshttps://doi.org/10.1016/j.autrev.2018.01.010openalex-snapshot
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.autrev.2019.102422openalex-snapshot
Aetiology and pathogenesis of paraneoplastic autoimmune disorders
inferred← citeshttps://doi.org/10.1016/j.berh.2019.03.009openalex-snapshot
Checkpoint inhibitor-associated autoimmunity
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2020.119926openalex-snapshot
Nanomaterials innovation as an enabler for effective cancer interventions
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110504openalex-snapshot
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
inferred← citeshttps://doi.org/10.1016/j.bpg.2017.04.007openalex-snapshot
Treatment of hepatitis B virus with combination therapy now and in the future
inferred← citeshttps://doi.org/10.1016/j.cclet.2022.01.011openalex-snapshot
Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics
inferred← citeshttps://doi.org/10.1016/j.clim.2018.12.003openalex-snapshot
The kaleidoscope of autoimmunity – From genes to microbiome
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2019.10.015openalex-snapshot
The life-threatening eruptions of immune checkpoint inhibitor therapy
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2020.06.011openalex-snapshot
Cutaneous immune-related adverse events to checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.clinimag.2017.12.014openalex-snapshot
Multimodality imaging of endocrine immune related adverse events: a primer for radiologists
inferred← citeshttps://doi.org/10.1016/j.clinimag.2020.02.006openalex-snapshot
Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist
inferred← citeshttps://doi.org/10.1016/j.coviro.2018.04.006openalex-snapshot
Perspectives and limitations for nucleo(t)side analogs in future HBV therapies
inferred← citeshttps://doi.org/10.1016/j.cpccr.2021.100091openalex-snapshot
Systemic lichenoid inflammation from immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1016/j.crad.2017.04.003openalex-snapshot
Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.crad.2020.11.117openalex-snapshot
Imaging spectrum of adverse events of immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.07.005openalex-snapshot
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103376openalex-snapshot
Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctro.2024.100731openalex-snapshot
Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissue
inferred← citeshttps://doi.org/10.1016/j.ctrv.2017.05.003openalex-snapshot
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
inferred← citeshttps://doi.org/10.1016/j.det.2024.02.012openalex-snapshot
Immune Checkpoint Inhibitor-Induced Psoriasis
inferred← citeshttps://doi.org/10.1016/j.disamonth.2021.101300openalex-snapshot
Oral mucositis: Current knowledge and future directions
inferred← citeshttps://doi.org/10.1016/j.ejca.2016.07.026openalex-snapshot
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
inferred← citeshttps://doi.org/10.1016/j.ejca.2016.12.038openalex-snapshot
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.05.042openalex-snapshot
Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.07.029openalex-snapshot
Nivolumab-associated nausea and vomiting as an immune adverse event
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.08.024openalex-snapshot
Diarrhoea during checkpoint blockade, not always colitis
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.09.014openalex-snapshot
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
inferred← citeshttps://doi.org/10.1016/j.ejca.2018.02.006openalex-snapshot
Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?
inferred← citeshttps://doi.org/10.1016/j.ejca.2018.02.019openalex-snapshot
Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient
inferred← citeshttps://doi.org/10.1016/j.ejca.2018.09.033openalex-snapshot
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejca.2019.08.014openalex-snapshot
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.11.027openalex-snapshot
The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
inferred← citeshttps://doi.org/10.1016/j.ejca.2021.01.005openalex-snapshot
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study
inferred← citeshttps://doi.org/10.1016/j.ejca.2022.08.029openalex-snapshot
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.113255openalex-snapshot
Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.113313openalex-snapshot
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.113505openalex-snapshot
The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
inferred← citeshttps://doi.org/10.1016/j.ejim.2017.08.019openalex-snapshot
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
inferred← citeshttps://doi.org/10.1016/j.ejpb.2024.114323openalex-snapshot
Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174593openalex-snapshot
A Brief look at antitumor effects of doxycycline in the treatment of colorectal cancer and combination therapies
inferred← citeshttps://doi.org/10.1016/j.ejrad.2020.109250openalex-snapshot
Imaging findings of immune checkpoint inhibitor associated pancreatitis
inferred← citeshttps://doi.org/10.1016/j.ejrad.2021.110062openalex-snapshot
Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events
inferred← citeshttps://doi.org/10.1016/j.ekir.2019.06.001openalex-snapshot
Anti−PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1
inferred← citeshttps://doi.org/10.1016/j.esmogo.2024.100083openalex-snapshot
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management
inferred← citeshttps://doi.org/10.1016/j.esmoop.2023.100787openalex-snapshot
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
inferred← citeshttps://doi.org/10.1016/j.eucr.2020.101145openalex-snapshot
Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report
inferred← citeshttps://doi.org/10.1016/j.eucr.2020.101339openalex-snapshot
Isolated penile ulceration after Nivolumab therapy for non-small cell lung carcinoma
inferred← citeshttps://doi.org/10.1016/j.gastre.2023.10.003openalex-snapshot
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2023.10.009openalex-snapshot
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
inferred← citeshttps://doi.org/10.1016/j.gore.2023.101235openalex-snapshot
Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e13543openalex-snapshot
Identify AGAP2 as prognostic biomarker in clear cell renal cell carcinoma based on bioinformatics and IHC staining
inferred← citeshttps://doi.org/10.1016/j.hrcr.2023.04.007openalex-snapshot
Penpulimab-induced complete atrioventricular block in a patient with metastatic renal cancer
inferred← citeshttps://doi.org/10.1016/j.ijid.2017.01.028openalex-snapshot
Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
inferred← citeshttps://doi.org/10.1016/j.ijom.2018.07.025openalex-snapshot
Drug-induced oral lichenoid reaction during nivolumab therapy
inferred← citeshttps://doi.org/10.1016/j.imlet.2020.02.008openalex-snapshot
Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109022openalex-snapshot
A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110414openalex-snapshot
Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.111799openalex-snapshot
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
inferred← citeshttps://doi.org/10.1016/j.iotech.2019.08.001openalex-snapshot
Germline genetic host factors as predictive biomarkers in immuno-oncology
inferred← citeshttps://doi.org/10.1016/j.jaad.2018.03.055openalex-snapshot
Hair disorders in patients with cancer
inferred← citeshttps://doi.org/10.1016/j.jaad.2018.08.055openalex-snapshot
Guidelines of care for the management of primary cutaneous melanoma
inferred← citeshttps://doi.org/10.1016/j.jaad.2020.04.105openalex-snapshot
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
inferred← citeshttps://doi.org/10.1016/j.jaad.2020.09.054openalex-snapshot
Cutaneous adverse events caused by immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.jaad.2021.03.094openalex-snapshot
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis
inferred← citeshttps://doi.org/10.1016/j.jacc.2018.02.037openalex-snapshot
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.jaci.2018.02.042openalex-snapshot
Immune checkpoint blockade therapy
inferred← citeshttps://doi.org/10.1016/j.jaci.2020.12.654openalex-snapshot
PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity
inferred← citeshttps://doi.org/10.1016/j.jconrel.2020.11.056openalex-snapshot
Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine
inferred← citeshttps://doi.org/10.1016/j.jdcr.2016.06.012openalex-snapshot
Pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab treatment for metastatic melanoma
inferred← citeshttps://doi.org/10.1016/j.jdcr.2016.11.002openalex-snapshot
Inverse lichenoid drug eruption associated with nivolumab
inferred← citeshttps://doi.org/10.1016/j.jdcr.2020.03.007openalex-snapshot
Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.jdcr.2022.11.020openalex-snapshot
Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy
inferred← citeshttps://doi.org/10.1016/j.jdcr.2023.02.008openalex-snapshot
A case of pembrolizumab-induced pigmented purpuric dermatosis
inferred← citeshttps://doi.org/10.1016/j.jdcr.2025.04.007openalex-snapshot
Scarring alopecia as an unexpected consequence of immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1016/j.jdermsci.2020.01.011openalex-snapshot
Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer
showing the first 200 of 647 · page through all 647
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.